Latest News for Jaguar Mining Stock (OTC:JAGGF)

Jaguar Mining Inc is a junior gold mining company. The company is engaged in producing gold, development, and exploration company operating in the Iron Quadrangle, a prolific greenstone belt located in Minas Gerais, Brazil. The company is focused on the acquisition, exploration, development, and operation of gold-producing properties in Brazil. The principal operating assets of the company are MTL Complex, Caete Complex, Paciencia Complex, Faina Project, Oncas De Pitangui Project, and others. The company also owns the Paciencia Gold Mine Complex.

As Gold Prices Reach Pre-War High, US Gold Corp Sees Its Reserve Value Soar

Penny Stocks

Commodities

Markets

GOLD

JAGGF

USAU

As the price of gold increases, U.S. Gold Corp (NASDAQ: USAU), a precious metals exploration and development company, has seen the value of its reserves soar.

Jaguar Mining Inc

Schlumberger N.V.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>) reported&nbsp;a first-quarter 2024 revenue&nbsp;increase of 13% year-over-year to $8.707 billion,&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/04/b38331337/slb-announces-first-quarter-2024-results-targeting-to-return-7-billion-to-shareholders-over-2024-2" rel="noreferrer noopener">beating the consensus of $8.689 billion.</a>
The company stated that almost half of the year-on-year revenue increase came from the Aker subsea business, which&nbsp;was added&nbsp;as part of our OneSubsea joint venture in the fourth quarter of 2023.
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/03/37977757/schlumberger-expands-carbon-capture-reach-through-aker-acc-deal-details" rel="noreferrer noopener">Schlumberger Expands Carbon Capture Reach Through Aker ACC Deal: Details</a>
Revenue by Division: Digital &amp; Integration $953 million (+7% Y/Y); Reservoir Performance $1.725 billion (+15% Y/Y); Well Construction $3.368 billion (+3% Y/Y), and Production Systems $2.82 billion (+28% Y/Y).
International revenue grew 18% Y/Y, with YoY growth of 29% in the Middle East &amp; Asia and 18% in Europe &amp; Africa. North American market revenue declined 6% Y/Y.
Adjusted EPS increased 19% Y/Y to $0.75, <a href="https://www.benzinga.com/calendars/earnings">which aligned with the consensus.</a>
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38328949/schlumberger-likely-to-report-higher-q1-earnings-here-are-the-recent-forecast-changes-from-wall-str" rel="noreferrer noopener">Schlumberger Likely To Report Higher Q1 Earnings; Here Are The Recent Forecast Changes From Wall Street&#8217;s Most Accurate Analysts</a>
Adjusted EBITDA was $2.06 billion for the quarter, an increase of 15% Y/Y, and margin expanded 51 bps to 23.6%. The pretax segment operating margin expanded by 95 bps for the quarter to 18.9%.
Operating cash flow for the quarter totaled $327 million compared to $330 million a year ago. Free cash flow was negative $(222 million.
Dividend:&nbsp;SLB declared a quarterly cash dividend of $0.275 per share, payable on July 11, 2024, to stockholders of record on June 5, 2024.
&#8220;We remain confident in our global revenue growth outlook for 2024, with softness in North America&nbsp;being offset&nbsp;by upside in the international markets,&#8221; CEO Olivier Le Peuch commented.
&#8220;Based on our strong start to the year, confidence in our ability to generate robust cash flows, and the anticipated contribution of the announced ChampionX acquisition, we are targeting to return $7 billion to shareholders over the next two years. This represents a target for returns to shareholders of $3 billion in 2024 and $4 billion in 2025.&#8221;
Related:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38054329/championx-schlumberger-shares-move-in-opposite-directions-after-8b-deal-announcement" rel="noreferrer noopener">ChampionX, Schlumberger Shares Move In Opposite Directions After $8B Deal&nbsp;Announcement</a>
During the quarter, SLB repurchased 5.4 million shares at an average price of $50.13 per share for $270 million.
Price Action: SLB shares are trading lower by 1.87% at $49.99 at the last check Friday.
Photo by Rab Lawrence via Flickr

Earnings

Equities

News

Dividends

Buybacks

Movers

Schlumberger's Strategic Expansion Pays Off: Surpasses Q1 Topline Expectations, Commits To $7B Shareholder Return

Taiwan Semiconductor Manufacturing Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) is adjusting its pricing model to include a premium for chips manufactured outside&nbsp;of&nbsp;Taiwan.&nbsp;
This move&nbsp;is driven&nbsp;by the need to expand its global production capabilities amid escalating tensions with China and rising production costs.&nbsp;
The key&nbsp;Nvidia Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) supplier&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38320056/whats-going-on-with-apple-supplier-taiwan-semi-stock-on-thursday" rel="noreferrer noopener">reported a robust</a>&nbsp;first-quarter net profit and anticipates revenue growth driven by AI chip demand.&nbsp;
It maintains a capital expenditure forecast of $28 billion&nbsp;&#8211; $32&nbsp;billion for the year but expects a slight dip in gross margin in the upcoming quarter due to increased costs.&nbsp;
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/24/04/38328610/tsmc-cautions-red-hot-chip-industry-growth-could-cool-amid-declining-automotive-chip-demand" rel="noreferrer noopener">TSMC Cautions Red-Hot Chip Industry Growth Could Cool Amid Declining Automotive Chip Demand</a>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="750" height="650" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19084245/newplot-20.png" alt="" class="wp-image-299905" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19084245/newplot-20.png 750w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19084245/newplot-20-300x260.png 300w" sizes="(max-width: 750px) 100vw, 750px" /></figure>
CEO CC Wei highlighted during the earnings call that these geographical-specific price adjustments are necessary to cover the increased expenses associated with operating in diverse locations due to the globalized nature of the industry.&nbsp;
The strategy aligns with global efforts to reduce reliance on Taiwan for semiconductor supplies, aiming to minimize geopolitical risks, especially considering China&#8217;s claims over Taiwan, First Post&nbsp;<a target="_blank" href="https://www.firstpost.com/tech/tsmc-to-charge-customers-more-for-semicon-chips-made-in-fabs-outside-taiwan-13761499.html" rel="noreferrer noopener">reports</a>.&nbsp;
TSMC&#8217;s investment in the U.S.&nbsp;is set&nbsp;to increase to $65 billion, reflecting a commitment to expanding its manufacturing footprint.&nbsp;This&nbsp;includes producing advanced 2-nanometer chips and establishing a new fabrication plant by 2030.
The company faces challenges such as higher power costs in Taiwan, impacts from an earthquake, and slower efficiency gains in its leading-edge 3-nanometer technology, affecting profitability.&nbsp;
Despite these hurdles, TSMC is optimistic about its future.&nbsp;It plans to initiate 2-nanometer chip production by late 2025, achieving&nbsp;a gross margin above 53%.
Taiwan Semiconductor stock&nbsp;has gained 52% in the last 12 months. Investors can gain exposure to the stock via&nbsp;the First Trust&nbsp;NASDAQ Technology Dividend Index Fund&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TDIV#NASDAQ">TDIV</a>) and&nbsp;the SPDR NYSE&nbsp;Technology ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XNTK#NYSE">XNTK</a>).
Price Action:&nbsp;TSM shares traded lower by 1.26% at $130.61 at&nbsp;the last check Friday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Jack Hong via Shutterstock

Tech

Media

NVDA

TDIV

XNTK

Pay More for Chips Made Outside Taiwan as AI Demand Soars and Global Expansion Continues, Taiwan Semiconductor

Macro Economic Events

Econ #s

Economics

IMF Assumes 'Full Reversal' Of Oil Output Cuts At Start Of 2025; Sees OPEC+ Starting To Lift Oil Output Gradually From July

Stephens &amp; Co. analyst Andrew Terrell maintains Banner (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANR#NASDAQ">BANR</a>) with a Overweight and lowers the price target from $54 to $53.

Price Target

Analyst Ratings

BANR

Stephens & Co. Maintains Overweight on Banner, Lowers Price Target to $53

Algorithm driven alerts help identify best antibiotic for patients with common infections in two 59-hospital trials, with implications to reduce antibiotic resistance
Two large multi-state studies uncovered a highly effective way to improve antibiotic selection for patients hospitalized with pneumonia or urinary tract infections (UTI), enabling better antibiotic stewardship in hospitals, according to research studies published today in the Journal of the American Medical Association (JAMA).
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F10.1001%2Fjama.2024.6248%3FguestAccessKey%3Db3f1c55d-c178-42cb-a223-8933eba2fec1%26utm_source%3DFor_The_Media%26utm_medium%3Dreferral%26utm_campaign%3Dftm_links%26utm_content%3Dtfl%26utm_term%3D041924__%3B%21%21OLgoXmg%21WNzHUWmXJwUyqQqaMIy_saDF846q5lWBwNWFydb5OOvGFjSRcGGDoOWUr-J2mhD36Zio7OQFkDd1Pmu-WQLaCu5b01LhRfU%24&amp;esheet=53939029&amp;newsitemid=20240419656742&amp;lan=en-US&amp;anchor=Stewardship+Prompts+to+Improve+Antibiotic+Selection+for+Pneumonia&amp;index=1&amp;md5=15a35e0df823412d643c8b9c0319747a">Stewardship Prompts to Improve Antibiotic Selection for Pneumonia</a> <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Furldefense.com%2Fv3%2F__https%3A%2Fjamanetwork.com%2Fjournals%2Fjama%2Ffullarticle%2F10.1001%2Fjama.2024.6259%3FguestAccessKey%3D7f813feb-2ef0-43b2-b612-fb4e0dec393f%26utm_source%3DFor_The_Media%26utm_medium%3Dreferral%26utm_campaign%3Dftm_links%26utm_content%3Dtfl%26utm_term%3D041924__%3B%21%21OLgoXmg%21WNzHUWmXJwUyqQqaMIy_saDF846q5lWBwNWFydb5OOvGFjSRcGGDoOWUr-J2mhD36Zio7OQFkDd1Pmu-WQLaCu5bnYwVQIw%24&amp;esheet=53939029&amp;newsitemid=20240419656742&amp;lan=en-US&amp;anchor=Stewardship+Prompts+to+Improve+Antibiotic+Selection+for+Urinary+Tract+Infection&amp;index=2&amp;md5=958f191b8e12e57c9ea2856f7d6e8ea7">Stewardship Prompts to Improve Antibiotic Selection for Urinary Tract Infection</a>
The studies, led by Harvard Pilgrim Health Care Institute, HCA Healthcare and the University of California, Irvine, were funded by the Centers for Disease Control and Prevention (CDC).
Antibiotic resistance, which occurs when germs like bacteria and fungi mutate to defeat the drugs designed to kill them, is a major public health threat. Helping clinicians tailor antibiotic prescriptions to individual patients can improve patient outcomes by preserving healthy bacteria in the body and reducing the risk of future antibiotic resistance.The two newly published studies, the INSPIRE Pneumonia and UTI Trials, involved more than 220,000 patients with pneumonia or UTI in 59 HCA Healthcare hospitals. In half of the hospitals, clinicians were given algorithm driven computerized alerts with information about the best antibiotic match for an individual patient at the moment antibiotics were being prescribed. This resulted in a better match for 28% of pneumonia patients and 17% of patients with UTI when compared to hospitals where physicians were not provided with alerts according to the trials.
The alerts used patient characteristics from the electronic medical record as well as hospital and location-specific data to determine the patient's risk for an antibiotic-resistant infection. Assessment of risk was based on pre-trial data from more than 200,000 HCA Healthcare patients with pneumonia and UTI. Physicians treating patients with a low risk for antibiotic-resistant bacteria were prompted to give standard-spectrum antibiotics.
"Pneumonia and urinary tract infections are two of the most common infections requiring hospitalization and a major reason for overuse of broad-spectrum antibiotics," said Sujan Reddy, MD, Medical Officer in the Epidemiology, Research and Innovations Branch of CDC's Division of Healthcare Quality Promotion. "The INSPIRE trials have found a highly effective way to help physicians follow treatment recommendations to optimize antibiotic selection for each patient. These trials show the value of harnessing electronic health data to improve best practice."
Physicians often choose extended-spectrum antibiotics that cover a very broad range of bacteria out of concern that their patients could be sick with antibiotic-resistant bacteria. The INSPIRE trials identified patients with low risk for antibiotic resistance and prompted physicians to order standard-spectrum antibiotics if extended-spectrum antibiotics were being ordered. The trials found that giving physicians real-time information about their patients' risk for antibiotic resistance worked significantly better to align antibiotic prescribing with current Infectious Diseases Society of America treatment recommendations.
"The right information at the right time can improve physician antibiotic selection," said Shruti Gohil, MD, MPH, Assistant Professor in the Division of Infectious Diseases at the University of California, Irvine School of Medicine. "Many different bacteria can cause pneumonia or UTI, and picking the best matched antibiotic can be a challenge. Results from these trials show that giving physicians an alert informing them of their patient's actual risk for antibiotic resistance can help them choose the best antibiotic and reduce extended-spectrum antibiotic use."
The INSPIRE trials were ongoing when the COVID-19 pandemic began. The trials showed continued beneficial effects in antibiotic selection when other hospitals in the nation were reporting large increases in use of extended-spectrum antibiotics. Part of this benefit is attributed to having an automated prompt that continues to work when hospital resources and staff attention are diverted.
The 59 participating community hospitals spanned 12 states and are part of HCA Healthcare, the largest private inpatient healthcare system in the U.S. The size of the studies involving a wide breadth of community hospitals supports the likelihood that results are applicable to hospitals across the country.
"HCA Healthcare is committed to excellence and innovation in delivering high-quality healthcare, and we are honored to continue our longstanding collaboration with the CDC, Harvard and UCI to leverage our health system's scale to answer clinical questions for the benefit of patients," said Kenneth Sands, MD, MPH, chief epidemiologist at HCA Healthcare. "We began using this groundbreaking technology and workflow in the hospitals where we tested it, and have since implemented it across our entire system to improve care for individual patients while also contributing to our growing body of work supporting appropriate antibiotic use everywhere."
The studies were conducted through a scientific consortium including HCA Healthcare, Harvard Medical School's Department of Population Medicine at the Harvard Pilgrim Health Care Institute, the University of California, Irvine and the Centers for Disease Control and Prevention.
Additional information about the INSPIRE Pneumonia and UTI Trials can be found in the following JAMA author interview podcast.

Biotech

General

Studies Led By Harvard Pilgrim Health Care Institute, HCA Healthcare And The University Of California, Irvine Announce Two Clinical Trials Identified A Better Way To Target Appropriate Antibiotics For Patients Hospitalized With Pneumonia Or Urinary Tract Infection

CJS Securities analyst Christopher Moore downgrades Encore Wire (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIRE#NASDAQ">WIRE</a>) from Market Outperform to Market Perform.

Downgrades

WIRE

CJS Securities Downgrades Encore Wire to Market Perform

Stephens &amp; Co. analyst Daniel Imbro maintains Marten Transport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRTN#NASDAQ">MRTN</a>) with a Overweight and lowers the price target from $23 to $21.

MRTN

Stephens & Co. Maintains Overweight on Marten Transport, Lowers Price Target to $21

Hilton Worldwide Holdings's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLT#NYSE">HLT</a>) short percent of float has risen 6.72% since its last report. The company recently reported that it has 3.17 million shares sold short, which is 1.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.31 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hilton Worldwide Holdings Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713533427_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hilton Worldwide Holdings has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hilton Worldwide Holdings's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hilton Worldwide Holdings's peer group average for short interest as a percentage of float is 6.01%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Peering Into Hilton Worldwide Holdings's Recent Short Interest

Kohl's's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>) short percent of float has risen 6.92% since its last report. The company recently reported that it has 29.91 million shares sold short, which is 37.7% of all regular shares that are available for trading. Based on its trading volume, it would take traders 5.35 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Kohl's Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713533421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Kohl's has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Kohl's's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Kohl's's peer group average for short interest as a percentage of float is 7.44%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(KSS) - Analyzing Kohl's's Short Interest

UnitedHealth Group's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) short percent of float has risen 6.33% since its last report. The company recently reported that it has 7.77 million shares sold short, which is 0.84% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.5 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>UnitedHealth Group Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713533416_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for UnitedHealth Group has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing UnitedHealth Group's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, UnitedHealth Group's peer group average for short interest as a percentage of float is 4.17%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into UnitedHealth Group's Recent Short Interest

In February, the Securities and Exchange Commission (SEC) announced the arrival of T+1, the new one-day securities trading settlement system. While the new system is still a few weeks away from implementation, traders could benefit from a settlement refresher and understanding of the violations that occur when trying to trade with unsettled funds.
Don't Miss:
<ul>
<li>This prop trading firm allows traders to receive 100% of the first $25,000 per account and 90% beyond that.<a href="https://www.benzinga.com/money/apex-trader-funding"> Heres how you can get in on the profit.</a></li>
</ul>
<h2 class="wp-block-heading">Settlement Rules And Consequences For Violations</h2>
Securities currently <a href="https://www.investor.gov/introduction-investing/general-resources/news-alerts/alerts-bulletins/investor-bulletins/new-t1-settlement-cycle-what-investors-need-know-investor-bulletin">settle under T+2</a>, which means two business days pass between the execution of a trade and the actual exchange of money and securities. For example, if you buy 100 shares of Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) on Tuesday, the position will appear in your portfolio, but your broker won't deliver your cash to the seller until Thursday.
Settlement time has gradually decreased as trading technology has improved. Shares were once traded using pieces of paper, which required actual physical delivery for settlement. With paper shares, it made sense to have a time window between the transaction agreement and the exchange of assets. But this also presents an opportunity for improper activity, like buying an asset and using the funds to buy and sell a separate asset before settlement of the original trade.
What happens if you attempt to buy securities with unsettled funds? Three types of violations exist for trading with unsettled cash:
<ul>
<li>Good faith violation (GFV): Imagine you have 100 shares of stock in your account. If you sell your 100 shares, your account will show a cash balance for the transaction. This cash is unsettled because the trade won't settle for two days. If you buy and sell another stock the next day, you'll receive a good faith violation for trading with unsettled funds. Most <a href="https://www.benzinga.com/money/best-futures-brokers">securities brokers</a> give a warning for the first GFV, but cash settlement restrictions will be administered for a second violation.</li>
</ul>
<ul>
<li>Freeriding violation: If you have $1,000 in your account and buy $2,000 worth of stock, you must supply the remaining $1,000 before settlement. You'll also need to hold the shares until the remaining cash is provided to avoid a freeriding violation. This violation is more severe and will result in a 90-day account freeze.</li>
</ul>
<ul>
<li>Liquidation violation: In a cash account, a liquidation violation occurs when shares of one stock are sold to meet the settlement requirements of a different stock. For margin accounts, a liquidation violation occurs when shares are sold to satisfy both maintenance and Fed margin calls. These consequences are the same as GFVs: first, a warning, then cash settlement restrictions. Note that margin accounts are required to trade certain securities like futures and <a href="https://www.benzinga.com/money/how-to-make-money-on-forex-trading">forex contracts</a>.</li>
</ul>
<h2 class="wp-block-heading">How Should Prop Traders Prepare For T+1?</h2>
The move to T+1 will benefit most prop traders. Reducing settlement time means traders can take advantage of more opportunities without waiting for funds to settle. Additionally, many settlement violations occur accidentally because of automated systems or a simple mistake. Moving to T+1 should decrease the number of unintentional violations applied to cash and margin accounts. Also, understand which securities settlement rules apply: Government bonds and options already operate on a T+1 schedule.
Have you been looking for an opportunity to up your trading game? Prop trading challenges, like the program from <a href="https://tradethepool.com/">Trade The Pool</a>, offer the chance to prove your worth in a simulated environment, using virtual accounts and cash with the opportunity for real profits. Use the 14-day free trial to test the demo account and see whether your trading skills are up to par.
Read Next:
<ul>
<li>Webull and Robinhood may have revolutionized stock market investing, but<a href="https://www.benzinga.com/money/apex-trader-funding"> this prop trading firm is reshaping the game for profitable traders</a>.</li>
<li>Finally, a stock trading prop firm! Find out how to trade over 12,000 stocks and ETFs, including penny stocks.<a href="https://www.benzinga.com/money/trade-the-pool"> Learn how you can get in on the action.</a></li>
</ul>

What Does The Upcoming T+1 Settlement Change Mean For Prop Traders?

As Bitcoin approaches the highly anticipated <a href="https://www.benzinga.com/topic/bitcoin-halving">Bitcoin halving</a>, a new research report by 10x Research identified a hidden factor that could derail the pre-halving hype and send Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38256809/bitcoins-weekend-selloff-a-healthy-shakeout-not-a-market-crash-expert-says">prices plummeting</a>.
What Happened: The <a href="https://mail.10xresearch.co/p/hidden-factor-send-bitcoin-plummeting-5200055000?utm_source=mail.10xresearch.co&amp;utm_medium=newsletter&amp;utm_campaign=the-hidden-factor-that-could-send-bitcoin-plummeting-to-52-000-55-000">report</a> from 10x Research authored by analyst Markus Thielen argues that recent trends in Bitcoin&#8217;s funding rate have become a cause for concern. 
The funding rate is a fee paid between perpetual swap holders based on the difference between the perpetual swap price and the spot price of Bitcoin. 
A negative funding rate suggests that more traders are holding short positions and thus, betting on a price decrease.
&#8220;This shift in sentiment,&#8221; writes Thielen, &#8220;indicates a potential reversal in the market. While Bitcoin may have been reacting favorably to earlier news, the funding rate suggests a growing number of investors anticipating a price drop.&#8221;
Why Macro Suddenly Matters
Thielen&#8217;s report highlights a crucial shift in Bitcoin&#8217;s price drivers. 
While the upcoming halving and ETF inflows previously dominated market narratives, macroeconomic factors, particularly inflation data, are now playing a more significant role.
The report cites historical examples where higher-than-expected inflation data triggered Bitcoin price corrections. 
In March, two such instances caused a 15% price drop. While subsequent reassurances from the Federal Reserve initially soothed investor concerns, recent inflation figures remain stubbornly high.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/digital-assets/ "><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27091545/Benzinga-conference.gif" alt="Benzinga future of digital assets conference" class="wp-image-267246" /></a></figure>
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38317307/bitcoin-halving-will-institutions-and-smart-money-upend-past-price-rallies">Bitcoin Halving: Will Institutions And &#8216;Smart Money&#8217; Upend Past Price Rallies?</a>
What Technical Analysis Says About Bitcoin
10x Research also points to a technical indicator — a Bitcoin price formation known as a triangle. In a bullish market, triangles often break upwards. 
However, there&#8217;s always a chance of a downward breakout.
&#8220;Should Bitcoin break below the triangle&#8217;s support level established around $68,000,&#8221; says Thielen, &#8220;we could potentially see a price drop equivalent to the triangle&#8217;s height, which translates to a decline towards $55,000.&#8221;
The report also identifies $52,000 as a critical Fibonacci retracement level. Fibonacci retracements are technical analysis tools used to identify potential support and resistance zones. 
If the $60,000 support level gives way, a further drop to $52,000 becomes a possibility.
What&#8217;s Next: With the May 1 FOMC meeting looming and inflation data remaining a key variable, the coming weeks could be a period of <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38288999/exclusive-how-the-bitcoin-halving-could-transform-the-market">heightened volatility for Bitcoin</a>.
Investors seeking to navigate these uncertainties and gain insights into the evolving economic and technical landscape are encouraged to attend Benzinga&#8217;s <a href="https://www.benzinga.com/events/digital-assets/agenda/">Future of Digital Assets</a> conference on Nov. 19.
Read Next:<a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38314438/jpmorgan-bitcoin-price-may-drop-after-halving-despite-miner-shakeup"> Bitcoin Price May Drop After Halving Despite Miner Shakeup: JPMorgan</a>
Image: Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Why Bitcoin Could Plummet To $52,000: 10x Research

Following an&nbsp;investigation&nbsp;announced in November last year, the FDA said on Thursday that it would now&nbsp;<a target="_blank" href="https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed" rel="noreferrer noopener">require</a>&nbsp;boxed warnings—the highest safety-related caution for medications—for all chimeric antigen receptor (CAR) T-cell therapies.&nbsp;
According to the agency, these blood cancer treatments may pose a&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-" rel="noreferrer noopener">risk of secondary cancers</a>.
The health regulator has required related updates to other&nbsp;label sections, such as warnings and precautions, postmarketing experience, patient counseling information, and medication guides.
The agency said patients and clinical trial participants receiving treatment with these products should be monitored lifelong for secondary malignancies and notify the manufacturer in the event of a new malignancy.
In November, the FDA said it received reports of patients developing T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35996543/eyes-on-novartis-gilead-bristol-myers-as-fda-weighs-risks-vs-benefits-of-approved-car-t-cell-ther" rel="noreferrer noopener">autologous CAR T cell immunotherapies</a>.
The agency said it&#8217;s weighing &#8220;the need for regulatory action&#8221; in response to clinical testing and safety monitoring reports tied to commercial use.&nbsp;
In&nbsp;January, the FDA asked drugmakers to add a boxed warning to their&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36736043/focus-on-bristol-myers-gilead-sciences-johnson-johnson-novartis-fda-to-issue-classwide-black-box-" rel="noreferrer noopener">CAR-T cancer therapies</a>.
In its January 19 notification letters, the agency stressed that the potential risk applies to all&nbsp;currently&nbsp;approved CAR-T products.&nbsp;
The regulatory body has mandated label updates for all six commercial CAR-T therapies, including&nbsp;Bristol Myers Squibb &amp; Co&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175623/download?attachment" rel="noreferrer noopener">Abecma</a>&nbsp;(partnered with partner&nbsp;2seventy bio&nbsp;Inc&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tsvt#NASDAQ">TSVT</a>))and&nbsp;<a target="_blank" href="https://www.fda.gov/media/175622/download?attachment" rel="noreferrer noopener">Breyanzi</a>,&nbsp;Johnson &amp; Johnson&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175624/download?attachment" rel="noreferrer noopener">Carvykti</a>&nbsp;(developed in partnership with&nbsp;Legend Biotech Corporation&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/legn#NASDAQ">LEGN</a>)),&nbsp;Novartis AG&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175625/download?attachment" rel="noreferrer noopener">Kymriah</a>, and&nbsp;Gilead Sciences Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)&nbsp;<a target="_blank" href="https://www.fda.gov/media/175627/download?attachment" rel="noreferrer noopener">Yescarta</a>.
Gilead&#8217;s Tecartus was also part of the list, but later, it was removed from <a href="https://www.benzinga.com/general/biotech/24/01/36760938/gileads-tecartus-dropped-from-fda-list-of-car-t-therapy-with-updated-label-warning-of-risks-of-se" target="_blank" rel="noreferrer noopener">boxed warning requirements</a>.
Photo via Shutterstock

Large Cap

Health Care

GILD

LEGN

TSVT

FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies

Stephens &amp; Co. analyst Daniel Imbro maintains P.A.M. Transportation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTSI#NASDAQ">PTSI</a>) with a Equal-Weight and lowers the price target from $19 to $17.

PTSI

Stephens & Co. Maintains Equal-Weight on P.A.M. Transportation, Lowers Price Target to $17

WIIM

FSLR

First Solar shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $187 to $250.

Truist Securities analyst Scot Ciccarelli maintains Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) with a Buy and raises the price target from $167 to $183.

Truist Securities Maintains Buy on Genuine Parts, Raises Price Target to $183

Israel launched a targeted airstrike near an Iranian military airbase overnight, as a retaliatory act to Iran&#8217;s aerial attacks that occurred less <a href="https://www.benzinga.com/news/24/04/38328453/iran-says-nuclear-facilities-safe-after-israeli-strike-us-confirms-escalation">than a week ago. </a>
Although the strike was described as limited, causing neither significant damage to the facility nor casualties, it has intensified uncertainties regarding the risk of a broader escalation within the Middle East.
<h4 class="wp-block-heading" id="h-political-reactions">Political Reactions</h4>
<ul>
<li>The Jerusalem Post interpreted the strike as Israel sending a &#8220;clear message&#8221; to Iran, emphasizing the proximity of the target to a key nuclear site and hinting at the potential for more severe actions. Israel&#8217;s National Security Minister, Itamar Ben Gvir, labeled the strike as &#8220;Feeble!&#8221; on social media X. Opposition leader Yair Lapid criticized Ben Gvir's approach, accusing him of harming Israel&#8217;s security and international standing.</li>
<li>Iranian officials told Reuters they do not intend to retaliate, signaling a desire to avoid further escalation. Just a day earlier, Iran's Foreign Minister, Hossein Amirabdollahian, told CNN during an exclusive interview that Iran&#8217;s next response &#8220;will be immediate and at a maximum level&#8221; in case Israel embarks &#8220;on adventurism again and takes actions against the interests of Iran.&#8221;</li>
<li>Global leaders also weighed in, with British Prime Minister Rishi Sunak stating that a "significant escalation is not in anyone's interest."</li>
<li>Speaking at the G7 meeting in Italy, U.S. Secretary of State Antony Blinken remarked that the U.S. has not been involved in any offensive operations. He reiterated the commitment to Israel's security and to "de-escalation" in the Middle East.</li>
<li>Italian Foreign Minister Antonio Tajani informed reporters that the United States had disclosed to the Group of Seven foreign ministers that it was notified at the last minute about the attack on Iran.</li>
<li>U.S. officials revealed that the Biden administration is contemplating new weapons deals for Israel worth over $1 billion, which would include tank ammunition, military vehicles, and mortar rounds, as per The <a href="https://www.wsj.com/world/biden-weighs-more-than-1-billion-in-new-arms-for-israel-8b8607e4?mod=Searchresults_pos1&amp;page=1">Wall Street Journal</a>. </li>
</ul>
<h4 class="wp-block-heading">Market Impact</h4>
The immediate market reaction saw oil prices surge above $90 a barrel, though they later fell after assurances of no further retaliatory measures from Iran. 
Gold prices briefly exceeded $2,400 per ounce, settling at around $2,380 as safe haven demand slightly faded. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) experienced wild volatility, dropping to as low as $59,500 when Israel carried out the strike before rebounding to $65,000, as risks of an escalation dissipated. 
Futures on major U.S. indices traded flat during premarket trading on Friday. The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) closed 0.2% lower on Thursday, notching its fifth straight session of declines. 
Chart: Markets React To Israeli Strikes In Iran
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19085108/image-124-1024x495.png" alt="" class="wp-image-299927" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19085108/image-124-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19085108/image-124-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19085108/image-124-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19085108/image-124-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/19085108/image-124.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read now: <a href="https://www.benzinga.com/general/macro-notification/24/04/38325320/small-group-of-hedge-funds-wields-dominance-in-us-treasury-market-a-concentration-of-v">Small Group Of Hedge Funds Wields Dominance In US Treasury Market: &#8216;A Concentration Of Vulnerability Has Built Up,&#8217; IMF Warns</a>
Photo: Shutterstock

Broad U.S. Equity ETFs

Specialty ETFs

Politics

Global

ETFs

Israel Strikes Iranian Air Base: Tehran Downplays Attack As Blinken Calls For Calm; Oil Prices Stabilize After Initial Spike

Wedbush analyst Michael Pachter maintains Roku (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Outperform and lowers the price target from $120 to $80.

ROKU

Wedbush Maintains Outperform on Roku, Lowers Price Target to $80

Truist Securities analyst David Macdonald reiterates Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Buy and raises the price target from $580 to $600.

Reiteration

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Truist Securities Reiterates Buy on Elevance Health, Raises Price Target to $600

Key Takeaways:
<ul>
<li>Nayuki&rsquo;s new store openings slowed in the first quarter due to seasonal factors, as it tweaked its franchising model aimed at boosting its presence in smaller cities</li>
<li>The premium tea seller will soon face new competition for investor dollars in Hong Kong, as at least five major rivals have filed for IPOs since last October</li>
</ul>
By Doug Young
Apart from fresh data showing a sharp slowdown in its store count growth and a slow start for its franchising business, the&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0418/2024041801185.pdf">latest quarterly update</a>&nbsp;from premium tea chain&nbsp;Nayuki Holdings Ltd.&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/nykhf#OTC">NYKHF</a>) is notable for one thing that&rsquo;s not included in the Thursday filing. That unspoken fact is that this will be the last time Nayuki issues such a report as the lone Hong Kong-listed company from China&rsquo;s crowded premium tea sector, also often referred to as bubble tea for one of its best-known products.
At least five other premium tea chains have filed to list in Hong Kong since last October, including industry leader&nbsp;Mixue, which filed for its IPO in January. Of those, only&nbsp;Sichuan Baicha Baidao, also known as Chabaidao, has been approved and officially launched its offering last week, underwritten by local powerhouse CICC as well as Citigroup.
The Chabaidao listing offers the first real valuation comparison to Nayuki, which has had the luxury of being the only choice from the bubble tea sector for investors since its listing in 2021. With all these new listings now coming to market, most of them much bigger in terms of store count, Nayuki will face far more competition to attract investor attention and will have to work extra hard to keep them interested in its story.
Nayuki and many of its peers suffered quite a bit during the pandemic since many of their stores were closed or faced other limits to their operations as part of China&rsquo;s strict Covid controls. What&rsquo;s more, their premium teas are mostly a &ldquo;feel good&rdquo; type of product that people often buy when engaged in the type of socializing that was quite limited during the pandemic.
As a result, Nayuki and many of its peers lost money during the pandemic and only returned to profitability last year with the lifting of restrictions. Accordingly, it&rsquo;s more useful to look at their price-to-sales (P/S) ratios when making comparisons to see who investors like, rather than the usual price-to-earnings (P/E) comparisons.
In that regard, Nayuki has P/S ratio of just 0.72, which looks quite low when one considers that any growth company should generally be valued above 1, and often much higher. Chabaidao&rsquo;s&nbsp;<a href="https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0415/2024041500022.pdf">IPO launch document</a>&nbsp;filed last week revealed it will have a market cap of about HK$26 billion ($3.3 billion) based on its IPO price of HK$17.50 per share. That would give it a P/S ratio of 1.4, or roughly double Nayuki, based on its 16.9 billion yuan ($2.33 billion) in revenue last year.
But Chabaidao&rsquo;s ratio is hardly anything to get too excited about either when compared with similar coffee chain operators. Shares of local coffee sensation&nbsp;Luckin&nbsp;(OTC: <a class="ticker" href="https://www.benzinga.com/stock/lkncy#OTC">LKNCY</a>) and&nbsp;Starbucks&nbsp;(NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sbux#NASDAQ">SBUX</a>), which counts China as its second largest market, both trade higher with P/S ratios of 2.1 and 2.7, respectively.
The key takeaway in this regard is that investors are quite wary about this new group of premium tea makers now coming to market due to the stiff competition that&rsquo;s likely to force some out of business in the years ahead. That means we&rsquo;ll probably see a healthy dose of pressure on the stocks as they flow onto the market in the next year or two.
<h3>Slow Growth</h3>
All that said, we&rsquo;ll return to the latest quarterly update that shows Nayuki&rsquo;s new store openings slowed considerably in the first quarter, which is typically slow due to cold weather that tends to discourage consumption. The company opened a net 23 new self-operated stores during the quarter, bringing its total to 1,597 by the end of March. The latest figure was sharply slower than 214 new stores openings in the fourth quarter, and 166 in the third.
But we should also note that the latest store count was up more than 70% from the company&rsquo;s 923 self-operated stores at the end of March 2023.
Nayuki also revealed for the first time that it had an additional 205 franchised stores in its network at the end of March, following its strategic decision last year to enter the franchising business. Still, the company&rsquo;s total of about 1,800 self-operated and franchised stores is far behind Chabaidao&rsquo;s nearly 8,000 stores at the end of last September, and is light years behind Mixue&rsquo;s industry-leading 36,000 stores at that time. Nearly all of Chabaidao&rsquo;s and Mixue&rsquo;s stores are franchised.
Nayuki also gave some of its first detailed discussion about progress for its franchising initiative, which is aimed at helping it expand into China&rsquo;s smaller third- and fourth-tier cities. That discussion appeared to show the company is still experimenting with the business model before attempting a more aggressive expansion that could help it to catch up with its larger rivals.
&ldquo;We optimized the requirements for franchisees in February 2024, as a result, the store model became more flexible, the requirements for areas have been lowered and the investment amount for single store also decreased to 580,000 yuan. These will help reduce capital pressure of franchisees and facilitate the continuous growth of the franchise business,&rdquo; it said.
Investors weren&rsquo;t too impressed with the latest report, bidding down Nayuki&rsquo;s shares by 3.8% in early Friday trade in Hong Kong. At that level, the stock is now down about 30% so far this year and is down 90% from its IPO price in 2021, reflecting the investor skepticism that we previously mentioned.
The franchising business will inevitably bring new issues for Nayuki, most notably due to quality control and margin pressure. The company&rsquo;s gross margin currently stands at about 40%, compared to 34% for Chabaidao, and about 31% for&nbsp;Auntea Jenny&nbsp;and&nbsp;Guming, two other large bubble tea chains that have filed to list in Hong Kong.
At the end of the day, investors probably won&rsquo;t be too excited about Nayuki&rsquo;s stock over the near- to medium-term due to all the new rivals coming to the Hong Kong Stock Exchange. But it could still potentially prove attractive over the longer haul if it can rapidly expand its franchising business without sacrificing its margins too much.
This article is from an unpaid external contributor. It does not represent Benzinga&#39;s reporting and has not been edited for content or accuracy.

Asia

LKNCY

NYKHF

SBUX

Nayuki Tweaks Franchising Model As Competitors Serve Up Rival Listings

Jaguar Mining: Cheap, But For A Reason

Jaguar Mining Inc. (TSE:JAG) has released an update. Jaguar Mining Inc. has reported a significant increase in their mineral reserves and resources...

Jaguar Mining Announces Reserves and Resources Surge

Jaguar Mining Inc. (TSE:JAG) has released an update. Jaguar Mining Inc. has announced positive outcomes from its 2023 exploration program across it...

Jaguar Mining Strikes Gold in Brazil Exploration

Jaguar Mining Inc. (TSE:JAG) has released an update. Jaguar Mining Inc. reported its 2023 annual results with a full-year gold production of 70,704...

Jaguar Mining 2023: Solid Profits Amidst Challenges

Jaguar Mining GAAP EPS of $0.14, revenue of $35.9M; initiates FY24 outlook

Jaguar Mining: An Undervalued Mid-Tier Gold Producer

Jaguar Mining Inc. (TSE:JAG) has released an update. Jaguar Mining Inc. has announced a decrease in gold production for Q1 2024, producing 16,177 o...

Jaguar Mining Reports Dip in Q1 Gold Production

Jaguar Mining Inc. (TSE:JAG) has released an update. Jaguar Mining Inc. has announced the sorrowful news of John Ellis' passing, a respected member...

Jaguar Mining Mourns Loss of Esteemed Director

Jaguar Mining: A Rough Start To The Year

Buying To The Bottom In Gold & Silver With Don Durrett

FNLPF

GDXJ

GOAU

HCHDF

HCHDY

PAAS

PAASF

PSLV

RING

SILJ

SILV

SSRGF

SSRM

Press Releases

Jaguar Mining Reports Third Quarter 2023 Results

Jaguar Mining Reports Updated Mineral Reserves and Mineral Resources for its MTL Complex Including Faina and Pitangui Projects

Jaguar Mining Reports Fourth Quarter and Full Year 2023 Production Results and Provides Outlook for 2024

Management

Jaguar Mining Strengthens Its Board With Appointment of CEO Vernon Baker as a New Director

Jaguar Mining Reports Updated Mineral Reserves and Mineral Resources

Jaguar Mining Accesses New High-Grade Mineralized Zone in Ba-Torre Structure

Jaguar Mining Provides Positive Results from Its 2023 Exploration Program

Jaguar Mining Reports Financial Results for the Fourth Quarter and Full Year 2023

Jaguar Mining Reports First Quarter 2024 Production Results

Jaguar Mining Announces Passing of Director John Ellis

TSX:JAG

Jaguar Mining

Jaguar Mining Q3 Sales $40.75M From $43.49M YoY

Intraday Update

AACAF

AACAY

AAGIY

AAIGF

AAMMF

AAUKF

AAVMY

AAVVF

ABBRF

ABCP

ABILF

ABMC

ABNAF

ABSSF

ACDVF

ACGBY

ACHFF

ACKRF

ACNDF

ACNNF

ACOPF

ACRL

ACSAY

ACUIF

ADAD

ADDDF

ADDYY

ADMT

ADYEY

AEGOF

AERG

AETUF

AEXAY

AFLYY

AGCBF

AGESY

AGFAF

AGGFF

AHCHY

AHEXY

AHGIF

AHKSF

AHKSY

AHWSF

AIBGY

AIBRF

AIQUY

AIRRF

AISSF

AJMPF

AJXGF

AKAOQ

AKBTY

AKZOY

ALBY

ALEAF

ALFVY

ALIAF

ALIF

Stocks That Hit 52-Week Highs On Tuesday

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Latest News for Jaguar Mining Stock (OTC:JAGGF)

Thursday, March 30, 2023

Monday, November 08, 2021

Tuesday, March 24, 2020